Early Onset of Clinical Improvement With Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 29 Aug 2016 Status changed from active, no longer recruiting to completed.
- 03 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Sep 2015 Planned End Date changed from 1 Jun 2017 to 1 Aug 2016 as reported by ClinicalTrials.gov record.